(444) Synchronized Codelivery of Dexamethasone and Propranolol for the treatment of Macular Degeneration

Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults worldwide [1]. It is a complex disease with many factors, like inflammation and angiogenesis, contributing to the progression of macular degeneration. Currently used first-line anti-VEGF therapies have limited efficacy owing to its complex etiology [2]. To address this, we explored a synergistic combination therapy using dexamethasone (DEX), an anti-inflammatory corticosteroid targeting the NF-κB pathway, and propranolol (PRO), an  anti-angiogenic beta-blocker act via modulation of the HIF-1α/VEGF pathway.